SOD1 and liver dysplastic nodule: Our findings revealed that mAPS administration decreased fasting blood glucose (FBG), BUN, SCR, UA, and MDA levels, while elevating serum GSH, GSH-PX, and SOD activities in DN rats (p < 0.05).